Literature DB >> 23343162

Nanomedicine in chemoradiation.

Seth M Miller1, Andrew Z Wang.   

Abstract

Chemoradiotherapy, the concurrent administration of chemotherapy and radiotherapy, is a treatment paradigm in oncology. It is part of the standard of care and curative treatment of many cancers. Given its importance, one of the primary goals of cancer research has been to identify agents and/or strategies that can improve the therapeutic index of chemoradiation. Recent advances in nanomedicine have provided a unique and unprecedented opportunity for improving chemoradiotherapy. Nanoparticles possess properties that are ideally suited for delivering chemotherapy in the chemoradiation setting. The goal of this review is to examine the role of incorporating nanomedicine into chemoradiation and the potential impact of nanomedicine to chemoradiotherapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23343162      PMCID: PMC3652407          DOI: 10.4155/tde.12.147

Source DB:  PubMed          Journal:  Ther Deliv        ISSN: 2041-5990


  106 in total

1.  Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.

Authors:  A N Gordon; J T Fleagle; D Guthrie; D E Parkin; M E Gore; A J Lacave
Journal:  J Clin Oncol       Date:  2001-07-15       Impact factor: 44.544

2.  Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis.

Authors:  Michael E Werner; Shrirang Karve; Rohit Sukumar; Natalie D Cummings; Jonathan A Copp; Ronald C Chen; Tian Zhang; Andrew Z Wang
Journal:  Biomaterials       Date:  2011-08-16       Impact factor: 12.479

3.  Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.

Authors:  M Overgaard; P S Hansen; J Overgaard; C Rose; M Andersson; F Bach; M Kjaer; C C Gadeberg; H T Mouridsen; M B Jensen; K Zedeler
Journal:  N Engl J Med       Date:  1997-10-02       Impact factor: 91.245

Review 4.  Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats.

Authors:  Michelle Longmire; Peter L Choyke; Hisataka Kobayashi
Journal:  Nanomedicine (Lond)       Date:  2008-10       Impact factor: 5.307

5.  Pegulated liposomal doxorubicin and cisplatin given concurrently with conventional radiotherapy: a phase I dose-escalation trial for patients with squamous cell carcinoma of head and neck and lung.

Authors:  H Varveris; S Kachris; M Mazonakis; E Lyraraki; A Markouizou; S Karabekios; A Tzedakis; K Perisinakis; J Damilakis; M Vlachaki
Journal:  Oncol Rep       Date:  2004-08       Impact factor: 3.906

Review 6.  Protein nanoparticles as drug carriers in clinical medicine.

Authors:  Michael J Hawkins; Patrick Soon-Shiong; Neil Desai
Journal:  Adv Drug Deliv Rev       Date:  2008-02-07       Impact factor: 15.470

7.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.

Authors:  M E R O'Brien; N Wigler; M Inbar; R Rosso; E Grischke; A Santoro; R Catane; D G Kieback; P Tomczak; S P Ackland; F Orlandi; L Mellars; L Alland; C Tendler
Journal:  Ann Oncol       Date:  2004-03       Impact factor: 32.976

Review 8.  Concept and clinical evaluation of carrier-mediated anticancer agents.

Authors:  William C Zamboni
Journal:  Oncologist       Date:  2008-03

9.  Polymeric nanoparticles containing taxanes enhance chemoradiotherapeutic efficacy in non-small cell lung cancer.

Authors:  Joohee Jung; Sung-Jin Park; Hye Kyung Chung; Hye-Won Kang; Sa-Won Lee; Min Hyo Seo; Heon Joo Park; Si Yeol Song; Seong-Yun Jeong; Eun Kyung Choi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-07-14       Impact factor: 7.038

10.  Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

Authors:  D W Northfelt; B J Dezube; J A Thommes; B J Miller; M A Fischl; A Friedman-Kien; L D Kaplan; C Du Mond; R D Mamelok; D H Henry
Journal:  J Clin Oncol       Date:  1998-07       Impact factor: 44.544

View more
  6 in total

Review 1.  Nanoparticles containing insoluble drug for cancer therapy.

Authors:  Shutao Guo; Leaf Huang
Journal:  Biotechnol Adv       Date:  2013-10-08       Impact factor: 14.227

Review 2.  Nanotechnology in radiation oncology.

Authors:  Andrew Z Wang; Joel E Tepper
Journal:  J Clin Oncol       Date:  2014-08-11       Impact factor: 44.544

Review 3.  Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care.

Authors:  Christopher M Hartshorn; Michelle S Bradbury; Gregory M Lanza; Andre E Nel; Jianghong Rao; Andrew Z Wang; Ulrich B Wiesner; Lily Yang; Piotr Grodzinski
Journal:  ACS Nano       Date:  2017-12-22       Impact factor: 15.881

4.  NQO1-dependent, Tumor-selective Radiosensitization of Non-small Cell Lung Cancers.

Authors:  Edward A Motea; Xiumei Huang; Naveen Singh; Jessica A Kilgore; Noelle S Williams; Xian-Jin Xie; David E Gerber; Muhammad S Beg; Erik A Bey; David A Boothman
Journal:  Clin Cancer Res       Date:  2019-01-07       Impact factor: 13.801

5.  Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery.

Authors:  Lisa Buckel; Elamprakash N Savariar; Jessica L Crisp; Karra A Jones; Angel M Hicks; Daniel J Scanderbeg; Quyen T Nguyen; Jason K Sicklick; Andrew M Lowy; Roger Y Tsien; Sunil J Advani
Journal:  Cancer Res       Date:  2015-02-13       Impact factor: 12.701

Review 6.  Delivery of Nanoparticle-Based Radiosensitizers for Radiotherapy Applications.

Authors:  Francis Boateng; Wilfred Ngwa
Journal:  Int J Mol Sci       Date:  2019-12-31       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.